Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization.
Recruiting · NCT07242534 · Interventional (participants receive a specific treatment) · Lead sponsor: Fundacion Dexeus
View the official record on ClinicalTrials.gov →Interventions studied
No pre-treatmentSemaglutide
What this trial is about
This is a randomized, controlled clinical trial with a two-sided superiority hypothesis. The study evaluates whether a 12-week pre-treatment with semaglutide prior to ovarian stimulation improves the number of good-quality blastocysts in overweight and obese women undergoing in vitro fertilization (IVF), compared to no pre-treatment.
Who can take part
Age range
18 Years to 38 Years
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- ≤ 38 years
- AMH \>= 1 ng/mL or AFC \>= 6
- Body mass index (BMI) between 27 kg/m2 and 40 kg/m2
- Scheduled for IVF with freeze-all strategy
Exclusion criteria
- Severe male factor (sperm concentration \<5M/mL)
- Type 2 diabetes mellitus
- Prior use of GLP-1 Ras within the past year
- Uncontrolled thyroid disorders
- Contraindications to IVF or semaglutide treatment
- Patients with chronic inflammatory diseases
- Family history of hereditary or chromosomal diseases
- Use of glucocorticoids or immunosuppressants
- PGT-A
- Use of medications affecting metabolism or inflammation
Where it is running
5 locations listed.
- Departamento de Ginecología Obstetricia y Reproducción. Hospital Universitari Dexeus - Barcelona, Spain
- Dexeus Mujer Tarragona - Tarragona, Spain
- Dexeus Mujer Sabadell - Sabadell, Barcelona, Spain
- Dexeus Mujer Sant Cugat - Sant Cugat del Vallès, Barcelona, Spain
- Dexeus Mujer Reus - Reus, Tarragona, Spain